INOZYME PHARMA, INC. Proceeds from Issuance Initial Public Offering
INOZYME PHARMA, INC. reported Proceeds from Issuance Initial Public Offering of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceInitialPublicOffering · last filed 2022-03-15
- INOZYME PHARMA, INC. proceeds from issuance initial public offering for the quarter ending 2020-12-31 was -$1.02M.
- INOZYME PHARMA, INC. proceeds from issuance initial public offering for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- INOZYME PHARMA, INC. proceeds from issuance initial public offering for fiscal 2020 was $115.97M.
| Period end | Proceeds from Issuance Initial Public Offering 3 month | Proceeds from Issuance Initial Public Offering 9 month | Proceeds from Issuance Initial Public Offering 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-15 | ||
| 2020-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $115.97M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $116.99M 10-Q · filed 2021-11-09 |